Gossamer Bio (GOSS) Stock Forecast & Price Target

$0.84 0.00 (-0.11%)

(As of 12/20/2024 05:31 PM ET)

Gossamer Bio - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 5 Analyst Ratings

Sell
0

Hold
0

Buy
5

Based on 5 Wall Street analysts who have issued ratings for Gossamer Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for GOSS.

Consensus Price Target

$9.20
995.24% Upside

According to the 5 analysts' twelve-month price targets for Gossamer Bio, the average price target is $9.20. The highest price target for GOSS is $15.00, while the lowest price target for GOSS is $4.00. The average price target represents a forecasted upside of 995.24% from the current price of $0.84.

Get the Latest News and Ratings for GOSS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gossamer Bio and its competitors.

GOSS Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.20	$9.20	$9.20	$3.75
Forecasted Upside	995.24% Upside	1,284.29% Upside	776.19% Upside	334.73% Upside
Consensus Rating	Buy	Buy	Buy	Hold

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

GOSS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GOSS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gossamer Bio Stock vs. The Competition

Type	Gossamer Bio	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	995.24% Upside	25,828.59% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent GOSS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00	+1,049.41%
8/13/2024	Wedbush 4 of 5 stars	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00	+403.14%
6/25/2024	Oppenheimer 3 of 5 stars	Initiated Coverage	Outperform	$9.00	+989.44%
6/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00	+1,316.41%
3/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$15.00	+1,204.34%
7/27/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $1.25	-0.79%
Get the Latest News and Ratings for GOSS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.
3/21/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight	$2.00 ➝ $1.50	+23.97%
3/7/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$5.00	+187.36%
2/28/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:39 AM ET.

GOSS Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Gossamer Bio is $9.20, with a high forecast of $15.00 and a low forecast of $4.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GOSS shares.
: According to analysts, Gossamer Bio's stock has a predicted upside of 995.24% based on their 12-month stock forecasts.
: Gossamer Bio has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like Gossamer Bio more than other "medical" companies. The consensus rating for Gossamer Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GOSS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Find out details on these three critical Nvidia partners immediately.

This page (NASDAQ:GOSS) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Stock Forecast & Price Target